Evaluation of adipose‐derived stromal vascular fraction or bone marrow‐derived mesenchymal stem cells for treatment of osteoarthritisDavid D. Frisbie John D. Kisiday Chris E. Kawcak Natasha M. Werpy C. Wayne McIlwraith
The purpose of this study was the assessment of clinical, biochemical, and histologic effects of intraarticular administered adipose‐derived stromal vascular fraction or bone marrow‐derived mesenchymal stem cells for treatment of osteoarthritis. Osteoarthritis was induced arthroscopically in the middle carpal joint of all horses, the contralateral joint being sham‐operated. All horses received treatment on Day 14. Eight horses received placebo treatment and eight horses received adipose‐derived stromal vascular fraction in their osteoarthritis‐affected joint. The final eight horses were treated the in osteoarthritis‐affected joint with bone marrow‐derived mesenchymal stem cells. Evaluations included clinical, radiographic, synovial fluid analysis, gross, histologic, histochemical, and biochemical evaluations. No adverse treatment‐related events were observed. The model induced a significant change in all but two parameters, no significant treatment effects were demonstrated, with the exception of improvement in synovial fluid effusion PGE2 levels with bone marrow‐derived mesenchymal stem cells when compared to placebo. A greater improvement was seen with bone marrow‐derived mesenchymal stem cells when compared to adipose‐derived stromal vascular fraction and placebo treatment. Overall, the findings of this study were not significant enough to recommend the use of stem cells for the treatment of osteoarthritis represented in this model.